These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 27026043)

  • 1. Interferon β-1a and Atorvastatin in the Treatment of Multiple Sclerosis.
    Ghasami K; Faraji F; Fazeli M; Ghazavi A; Mosayebi G
    Iran J Immunol; 2016 Mar; 13(1):16-26. PubMed ID: 27026043
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination therapy with interferon beta-1a and sesame oil in multiple sclerosis.
    Faraji F; Hashemi M; Ghiasabadi A; Davoudian S; Talaie A; Ganji A; Mosayebi G
    Complement Ther Med; 2019 Aug; 45():275-279. PubMed ID: 31331574
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic effect of vitamin D3 in multiple sclerosis patients.
    Mosayebi G; Ghazavi A; Ghasami K; Jand Y; Kokhaei P
    Immunol Invest; 2011; 40(6):627-39. PubMed ID: 21542721
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Atorvastatin combined to interferon to verify the efficacy (ACTIVE) in relapsing-remitting active multiple sclerosis patients: a longitudinal controlled trial of combination therapy.
    Lanzillo R; Orefice G; Quarantelli M; Rinaldi C; Prinster A; Ventrella G; Spitaleri D; Lus G; Vacca G; Carotenuto B; Salvatore E; Brunetti A; Tedeschi G; Brescia Morra V
    Mult Scler; 2010 Apr; 16(4):450-4. PubMed ID: 20150398
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ω-3 fatty acid treatment in multiple sclerosis (OFAMS Study): a randomized, double-blind, placebo-controlled trial.
    Torkildsen O; Wergeland S; Bakke S; Beiske AG; Bjerve KS; Hovdal H; Midgard R; Lilleås F; Pedersen T; Bjørnarå B; Dalene F; Kleveland G; Schepel J; Olsen IC; Myhr KM
    Arch Neurol; 2012 Aug; 69(8):1044-51. PubMed ID: 22507886
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG).
    Jacobs LD; Cookfair DL; Rudick RA; Herndon RM; Richert JR; Salazar AM; Fischer JS; Goodkin DE; Granger CV; Simon JH; Alam JJ; Bartoszak DM; Bourdette DN; Braiman J; Brownscheidle CM; Coats ME; Cohan SL; Dougherty DS; Kinkel RP; Mass MK; Munschauer FE; Priore RL; Pullicino PM; Scherokman BJ; Whitham RH
    Ann Neurol; 1996 Mar; 39(3):285-94. PubMed ID: 8602746
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of interferon-beta and atorvastatin on Th1/Th2 cytokines in multiple sclerosis.
    Sellner J; Greeve I; Findling O; Kamm CP; Minten C; Engelhardt B; Grandgirard D; Leib SL; Mattle HP
    Neurochem Int; 2008 Jul; 53(1-2):17-21. PubMed ID: 18524417
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictive value of early serum cytokine changes on long-term interferon beta-1a efficacy in multiple sclerosis.
    Petek-Balcı B; Çoban A; Shugaiv E; Türkoğlu R; Ulusoy C; İçöz S; Pehlivan M; Tüzün E; Akman-Demir G; Kürtüncü M; Eraksoy M
    Int J Neurosci; 2015 May; 125(5):352-6. PubMed ID: 25026220
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of TNF-alpha mRNA by peripheral blood mononuclear cells of multiple sclerosis patients treated with IFN-beta 1A.
    Sarchielli P; Critelli A; Greco L; Sokola E; Floridi A; Gallai V
    Cytokine; 2001 Jun; 14(5):294-8. PubMed ID: 11444910
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Less Frequent and Less Severe Flu-Like Syndrome in Interferon Beta-1a Treated Multiple Sclerosis Patients with at Least One Allele Bearing the G>C Polymorphism at Position -174 of the IL-6 Promoter Gene.
    Bertoli D; Serana F; Sottini A; Cordioli C; Maimone D; Amato MP; Centonze D; Florio C; Puma E; Capra R; Imberti L
    PLoS One; 2015; 10(8):e0135441. PubMed ID: 26285213
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Methylprednisolone in combination with interferon beta-1a for relapsing-remitting multiple sclerosis (MECOMBIN study): a multicentre, double-blind, randomised, placebo-controlled, parallel-group trial.
    Ravnborg M; Sørensen PS; Andersson M; Celius EG; Jongen PJ; Elovaara I; Bartholomé E; Constantinescu CS; Beer K; Garde E; Sperling B
    Lancet Neurol; 2010 Jul; 9(7):672-80. PubMed ID: 20542736
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combining beta interferon and atorvastatin may increase disease activity in multiple sclerosis.
    Birnbaum G; Cree B; Altafullah I; Zinser M; Reder AT
    Neurology; 2008 Oct; 71(18):1390-5. PubMed ID: 18525027
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Determination of cytokine levels in multiple sclerosis patients and their relevance with patients' response to Cinnovex.
    Taheri M; Ghafouri-Fard S; Solgi G; Sayad A; Mazdeh M; Omrani MD
    Cytokine; 2017 Aug; 96():138-143. PubMed ID: 28399486
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Simvastatin treatment in patients with relapsing-remitting multiple sclerosis receiving interferon beta 1a: a double-blind randomized controlled trial.
    Togha M; Karvigh SA; Nabavi M; Moghadam NB; Harirchian MH; Sahraian MA; Enzevaei A; Nourian A; Ghanaati H; Firouznia K; Jannati A; Shekiba M
    Mult Scler; 2010 Jul; 16(7):848-54. PubMed ID: 20488825
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination therapy with interferon beta-1a and doxycycline in multiple sclerosis: an open-label trial.
    Minagar A; Alexander JS; Schwendimann RN; Kelley RE; Gonzalez-Toledo E; Jimenez JJ; Mauro L; Jy W; Smith SJ
    Arch Neurol; 2008 Feb; 65(2):199-204. PubMed ID: 18071030
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neutralizing antibodies and efficacy of interferon beta-1a: a 4-year controlled study.
    Kappos L; Clanet M; Sandberg-Wollheim M; Radue EW; Hartung HP; Hohlfeld R; Xu J; Bennett D; Sandrock A; Goelz S;
    Neurology; 2005 Jul; 65(1):40-7. PubMed ID: 16009883
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Atorvastatin calcium in combination with methylprednisolone for the treatment of multiple sclerosis relapse.
    Li XL; Zhang ZC; Zhang B; Jiang H; Yu CM; Zhang WJ; Yan X; Wang MX
    Int Immunopharmacol; 2014 Dec; 23(2):546-9. PubMed ID: 25448497
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group.
    Lancet; 1998 Nov; 352(9139):1498-504. PubMed ID: 9820297
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX): a phase 3 randomised controlled trial.
    Comi G; De Stefano N; Freedman MS; Barkhof F; Polman CH; Uitdehaag BM; Casset-Semanaz F; Hennessy B; Moraga MS; Rocak S; Stubinski B; Kappos L
    Lancet Neurol; 2012 Jan; 11(1):33-41. PubMed ID: 22146409
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study.
    Khatri B; Barkhof F; Comi G; Hartung HP; Kappos L; Montalban X; Pelletier J; Stites T; Wu S; Holdbrook F; Zhang-Auberson L; Francis G; Cohen JA;
    Lancet Neurol; 2011 Jun; 10(6):520-9. PubMed ID: 21571593
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.